Advances in Antidepressant Therapy: Comparing the Efficacy of Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), and Novel Agents.

Introduction Depression is a prevalent and debilitating condition that often requires long-term medication management. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are commonly used but have limitations in efficacy and tolerability for some individuals. New antidepressant drugs targeting multiple pathways have shown potential in recent research. This study aimed to evaluate the efficacy, quality of life (QoL) improvements, and adverse effect profiles of SSRIs, SNRIs, and novel agents in patients with depression. Methodology This prospective cohort study was conducted at inpatient and outpatient psychiatric units of Abbas Institute of Medical Sciences, over six months, from March to August 2024, enrolling 300 patients diagnosed with depression. Participants were evenly divided into three treatment groups: SSRIs, SNRIs, and novel agents. Depression severity was assessed using the Hamilton Depression Rating Scale (HAM-D), and QoL was measured using standardized QoL scores. Statistical analyses, including paired t-tests, Analysis of Variance (ANOVA), and chi-square tests, were performed for comparison. Results All groups showed notable declines in Hamilton Depression Rating Scale (HAM-D) scores; the group with the new agents showed the largest mean HAM-D reduction: (17.2, p < 0.001). All groups' QoL rose; the mean rise in QoL ratings among the novel agents' group (19.7, p < 0.01) was the highest. Compared to SSRIs (84%) and SNRIs (82%), the novel agent group likewise had the lowest incidence of side effects, which raised the adherence rate (91%). Conclusion Novel antidepressants showed better efficacy and tolerability than SSRIs and SNRIs, therefore enhancing QoL and adherence. These findings imply that for those who do not react well to conventional treatments, novel medicines could be a good substitute. Confirming these conclusions will require more long-term, multi-center research.